Preeclampsia
Conditions
Brief summary
Introduction: Vanadium important pollutants produced from anthropogenic activities, has been suggested to be embryotoxic and fetotoxic in a lot of studies. Magnesium sulfate therapy is used very common to prevent seizures in women with preeclampsia. However, the causes of preeclampsia are little known and heavy metals merit further investigation. The investigators will be tested whether late - onset preeclampsia (LOPE) was associated with exposure to these metals. Methods: This study was designed to determine maternal plasma/urine/hair magnesium and vanadium concentrations in women with LOPE (n=70) compared to those of normotensive pregnant women (n=70) and to those of normotensive-healthy non-pregnant women (n=70). These metals concentrations will be measured using inductively coupled plasma-mass spectrometry were compared.
Detailed description
This observational case-control study will be conducted at the Department of Obstetrics and Gynecology, Cengiz Gokcek Public Hospital, Gaziantep, Turkey, between May 2020 and February 2021. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (reference no: 2020/130). The study strictly will be adhered to the principles of the Declaration of Helsinki. All participants will be included in the study gave oral and written informed consent. Two-hundred ten women will be enrolled in the study in three groups.
Interventions
OTHERmagnesium and vanadium measurements and compare
Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
Sponsors
Cengiz Gokcek Women's and Children's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Inclusion criteria
* preeclampsia * healthy pregnancy * healthy women
Exclusion criteria
1. pregnant women with any systemic condition (such as chronic hypertension, renal disease and diabetes mellitus) 2. using any kind of medication/supplement intake throughout pregnancy (such as heparin) 3. history of medication for PE treatment at the time of first admission 4. smoking 5. drug user 6. patients who had fetal congenital abnormalities or genetic syndromes 7. multiple-gestation pregnancies 8. pregnancies resulting from in vitro fertilization 9. intrauterine fetal death 10. having a family history of preeclampsia 11. Women who have menstrual irregularity 12. Women who have dyed their hair in the last 9 months 13. Gestational diabetes mellitus 14. Women receiving vanadium and/or magnesium treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| magnesium and vanadium levels | 10 day | The primary outcome in these analyses will be magnesium and vanadium levels in LOPE group and control groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| magnesium and vanadium levels in severy LOPE group | 1 day | The secondary outcome will be compare the magnesium and vanadium levels in mild LOPE group and severy LOPE group. |
Other
| Measure | Time frame | Description |
|---|---|---|
| magnesium and vanadium levels in SGA group | 1 day | Tertiary outcome will be compared the magnesium and vanadium levels in SGA group and non-SGA group. |
Countries
Turkey (Türkiye)
Outcome results
None listed